Diabetic Neuropathies Clinical Trial
Official title:
Short-term Effect of Podiatric Callus Debridement on Plantar Pressure in Diabetic Neuropathic Patients
Diabetes peripheral neuropathy (DPN) affects up to 50% of the diabetes population. In the diabetic neuropathic foot, it commonly manifests as loss of protective sensation, foot deformity and skin dryness. Alongside with day-to-day weightbearing activities, this can lead to formation of callus over plantar pressure points. Studies have proven that callus formation leads to high plantar pressure and increased risk of diabetic foot ulcers. For podiatrists, diabetic foot screening and treatment is our daily practice. Plantar callus are commonly treated by sharp debridement to relief pressure from the hard skin build up and thus reducing the risk of ulceration. However, the effectiveness of callus sharp debridement is not commonly studied in researches. Only a few studies in the past evaluated the effectiveness of callus treatment by different outcome measurements. Among those studies only 2 were specifically done in diabetic patients, in which one reported results of diabetic neuropathic patients. All the available studies used peak plantar pressure only as their pedobarographic outcome measure. In this study, the treatment effect of podiatric sharp debridement of callus in diabetic neuropathic patients will be evaluated using a range of pedobarographic parameters and Foot and Ankle Outcome Score (FAOS) questionnaire. The immediate and short-term (3-4 weeks) effect of sharp debridement in DPN patients with callus could be quantified. Change in loading pattern could also be analysed based on different areas of the foot.
Status | Recruiting |
Enrollment | 16 |
Est. completion date | April 30, 2024 |
Est. primary completion date | April 20, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age 18 or older 2. Active out-patient status in Podiatry department of Princess Margaret Hospital 3. Men and women 4. Ambulatory 5. Diagnosis of type I or II diabetes 6. Failed peripheral neurological assessment (Vibration perception threshold >25 volts or unable to detect one or more sites of 4-point 10g Semmes-Weinstein monofilament test) 7. Presence of plantar callus 8. Compliance with instructions (in Chinese or english) 9. Ability to read and write (in Chinese or english) Exclusion Criteria: 1. Peripheral vascular disease 2. Painful neuropathy 3. Charcot deformity 4. Undergone any form of callus debridement in the past 6 weeks 5. Active foot ulcer 6. Any dermatological condition other than callus that causes hyperkeratosis (e.g. verruca pedis, eczema, tinea pedis) 7. Any musculoskeletal condition that affects balance and gait 8. Allergic to chlorhexidine gluconate or alcohol |
Country | Name | City | State |
---|---|---|---|
Hong Kong | Podiatry Department, Princess Margaret Hospital | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
Chinese University of Hong Kong | Princess Margaret Hospital, Hong Kong |
Hong Kong,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Peak plantar pressure (PPP) (unit: kPa) | The maximum or highest pressure within foot | Before treatment, immediately after treatment and 3-4 weeks post-treatment | |
Secondary | Pressure time integral (PTI) (unit: kPa*sec) | The amount of pressure relative to the time that the pressure is present | Before treatment, immediately after treatment and 3-4 weeks post-treatment | |
Secondary | Peak pressure gradient (PPG) (unit: kPa/cm) | Spatial change in pressure around location of the peak pressure | Before treatment, immediately after treatment and 3-4 weeks post-treatment | |
Secondary | Forefoot to rearfoot peak pressure ratio (F/R ratio) | Forefoot to rearfoot peak plantar pressure ratio | Before treatment, immediately after treatment and 3-4 weeks post-treatment | |
Secondary | Foot and Ankle Outcome Score (FAOS) | Patient-reported outcome measurement (PROM) tool that is calculated using 42 Likert scale questions which are organised into 5 sub-categories: symptoms, pain, activities of daily living (ADL), sports and quality of life (QOL) | Before treatment, 1 week after treatment and 3-4 weeks post-treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05683106 -
Effects of Customized Silicone Digital Orthoses in People With Diabetic Neuropathy
|
N/A | |
Withdrawn |
NCT04106050 -
Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy
|
Phase 1 | |
Completed |
NCT04088929 -
The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Peripheral Neuropathy
|
Phase 2 | |
Completed |
NCT01939366 -
Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves
|
Phase 2 | |
Withdrawn |
NCT00815932 -
The Effect of Transcranial Direct Current Stimulation (t-DCS) On the P300 Component of Event-Related Potentials in Patients With Chronic Neuropathic Pain Due To CRPS or Diabetic Neuropathy
|
N/A | |
Completed |
NCT01926522 -
Technological Rehabilitation of Distal Sensorimotor Polyneuropathy in Diabetic Patients
|
N/A | |
Not yet recruiting |
NCT01180608 -
Functional Imaging of the Therapeutic Effect of Pregabalin in Treatment for Neuropathic Pain
|
N/A | |
Completed |
NCT00760955 -
Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy
|
Phase 2 | |
Completed |
NCT00380913 -
Evaluation of the Efficacy of Cesametâ„¢ for the Treatment of Pain in Patients With Diabetic Peripheral Neuropathy
|
Phase 4 | |
Terminated |
NCT00756041 -
Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy
|
Phase 2 | |
Completed |
NCT05255497 -
The Effect of Sensorial Biodex Balance Balance System Exercises in Diabetic Neuropathy
|
N/A | |
Completed |
NCT06061237 -
Effects of Aerobic Thai Dance in Patient With Diabetic Peripheral Neuropathy
|
N/A | |
Terminated |
NCT02915263 -
The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes
|
Phase 2 | |
Enrolling by invitation |
NCT05043636 -
Diabetic Neuropathy Screening Study 1.1 + Substudy 1.2-1.3-1.4
|
||
Completed |
NCT06373809 -
Placenta Derived Stem Cells for Treating of Chronic Ulcers and Neuropathy
|
Early Phase 1 | |
Completed |
NCT05968131 -
Comparative Effects of Proprioceptive Training and Routine Physical Therapy on Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT00282685 -
Safety and Feasibility Study of Autologous Progenitor Cell Transplantation in Diabetic Neuropathy
|
Phase 1 | |
Completed |
NCT00135109 -
Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy
|
Phase 3 | |
Completed |
NCT06292962 -
Evaluating the Impact of Vagus Nerve Stimulation on Diabetic Peripheral Neuropathic Pain
|
N/A | |
Completed |
NCT05058807 -
Effects of Whole Body Vibration in Diabetic Peripheral Neuropathy .
|
N/A |